| ORIGINAL ARTICLE |
|
| Year : 2022 | Volume
: 18
| Issue : 78 | Page : 256-260 |
|
|
Commigileadin A: A new triterpenoid from Commiphora gileadensis aerial parts
Hossam M Abdallah1, Gamal A Mohamed2, Sabrin R M. Ibrahim3, Abdulrahman E Koshak2, Ibrahim Alnashri2, Abdullah Alghamdi2, Abdulghani Aljohani2, Abdulrahman Khairy2
1 Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Cairo, Egypt
2 Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia
3 Department of Chemistry, Preparatory Year Program, Batterjee Medical College, Jeddah, Saudi Arabia; Department of Pharmacognosy, Faculty of Pharmacy, Assiut University, Assiut, Egypt
Correspondence Address:
Gamal A Mohamed
Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah - 21589
Saudi Arabia
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/pm.pm_118_21
|
|
|
Background: Genus Commiphora (Burseraceae) includes about 150 species of aromatic shrubs located in Africa, India, and the Arabian region. C. gileadensis L. has been used for treating several ailments such as constipation, urinary retention, headache, jaundice, joint pain, liver and stomach diseases, and inflammatory disorders. Objectives: In this work, a phytochemical investigation of C. gileadensis aerial parts was carried out. Moreover, the antimicrobial potential of the new metabolite was assessed. Materials and Methods: The aerial parts were extracted at room temperature with methanol (MeOH). The MeOH extract was subjected to various chromatographic techniques to separate the bio-constituents. Their structures were exhaustively specified by utilizing diversified spectroscopic data and comparing them with the literature. The antimicrobial potential of the new compound 1 was assessed toward Bacillus cereus, Escherichia coli, Staphylococcus aureus, and Clostridium albicans. Results: A new friedelan triterpenoid, commigileadin A [3,11-dioxo-(D: A)-friedo-olean-27-al] (1) and four known metabolites, namely, Stigmasterol (2), naringenin (3), naringenin-4-methyl ether (4), and kaempferol (5) were obtained. Compound 1 possessed moderate activity toward B. cereus (inhibition zone diameter (IZD): 12.6 mm and minimum inhibitory concentration [MIC]: 8.9 μg/mL) in comparison to ciprofloxacin (IZD: 21.1 mm and MIC: 2.5 μg/mL, respectively). Conclusion: This work reported the characterization of a new triterpenoid (1) and four known constituents (2-5). Compound 1 possessed a moderate activity toward B. cereus.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
